Category: 53838-27-0

Moroder, Luis; Borin, Gianfranco; Filippi, Bruno; Stivanello, Diego; Marchiori, Fernando published an article in 1977, the title of the article was Studies on cytochrome c. XII. Synthesis of the protected undecapeptide (sequence 66-76) and pentadecapeptide (sequence 66-80) of horse heart cytochrome c.COA of Formula: C10H19NO4 And the article contains the following content:

Z-Glu-Tyr-Leu-Glu-Asn-Pro-Lys(TFA)-Lys(TFA)-Tyr-Ile-Pro-NHNH2 (I; Z = PhCH2O2C, TFA = CF3CO), the protected 66-76 fragment of horse heart cytochrome c was prepared by coupling Z-Glu(OCMe3)-Tyr-Leu-Glu(OCMe3)-NHNH2 (II) to H-Asn-Pro-Lys(TFA)-Lys(TFA)-Tyr(CMe3)-Ile-Pro-NHNHCO2CMe3 by the azide method and partially deblocking the resulting undecapeptide with CF3CO2H. I was coupled to H-Gly-Thr(CMe3)-Lys(TFA)-Met-NHNHCO2Me3 (III) by the azide method to give the corresponding protected pentadecapeptide which was the protected 66-80 fragment of cytochrome c. II and III were prepared by conventional stepwise peptide couplings. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).COA of Formula: C10H19NO4

The Article related to cytochrome c undecapeptide pentadecapeptide synthesis, Synthesis of Amino Acids, Peptides, and Proteins: Peptides and other aspects.COA of Formula: C10H19NO4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On October 1, 2015, Brownstein, Michael J. published a patent.Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of substituted azetidinone derivatives for use in the treatment of neurodegenerative diseases. And the patent contained the following:

Title compounds I [A = carboxylic acid, ester, or amide; D = carboxylic acid, ester, amide, alc., or thiol; R1 = H or alkyl; R2 = H, CN, halo, alkyl, etc.; R3 = (un)substituted amino, amido, acylamido, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed for use in the treatment of neurodegenerative diseases. Thus, e.g., II was prepared by a multistep procedure (preparation given). Select I were evaluated in Via receptor binding assays, e.g., II demonstrated an IC50 value of 2.92 nM. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to azetidinone preparation neurodegenerative disease, Heterocyclic Compounds (One Hetero Atom): 4-Membered Rings and other aspects.Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 21, 2019, Brownstein, Michael J. published a patent.Application In Synthesis of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the patent was Preparation of azetidinone derivatives for use in treating brain injury. And the patent contained the following:

Title compounds I [A = CO2H, ester, or amide; B = OH, SH, CO2H, ester, or amide; R1 = H or alkyl; R2 = H, halo, CN, alkyl, alkoxy, etc.; R3 = amino, amido, acylamido, (un)substituted ureido, etc.; R4 = alkyl, (un)substituted aryl, arylalkyl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed for use in treating brain injurys. Thus, e.g., II was prepared by a multistep procedure (preparation given). Select I were evaluated in V1a binding assays, e.g., II demonstrated an IC50 value of 0.49 nM. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Application In Synthesis of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to azetidinone preparation brain injury, Heterocyclic Compounds (One Hetero Atom): 4-Membered Rings and other aspects.Application In Synthesis of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 7, 1977, Wuensch, Erich; Wendlberger, Gerhard; Jaeger, Ernst published a patent.COA of Formula: C10H19NO4 The title of the patent was L-Leucine-13-motiline. And the patent contained the following:

H-Phe-Val-Pro-Ile-Phe-Thr-Tyr-Gly-Glu-Leu-Gln-Arg-Leu-Glu-Glu-Lys-Glu-Arg-Asn-Lys-Gly-Gln-OH (I), 13-L-leucine-motiline, was prepared by peptide fragment condensations. Thus, Z-Asn-Lys(BOC)-OH (Z = PhCH2O2C, BOC = Me3CO2C) and H-Gly-Gln-OCMe3 were prepared and coupled together by dicyclohexylcarbodiimide (DCC) in the presence of N-hydroxysuccinimide (HOSu) to give the protected tetrapeptide. The latter was Z-deblocked by hydrogenation and then coupled to Z-Arg(Z2)-OC6H4NO2-4 to give the protected pentapeptide which was hydrogenated and treated with HBr to give H-Arg-Asn-Lys(BOC)-Gly-Gln-OCMe3.2HBr (II), the protected 18-22 sequence of I. Z-Glu(OCMe3)-Glu(OCMe3)-Lys(BOC)-Glu(OCMe3)-OH (III), the 14-17 sequence, Z-Arg(Z2)-Leu-OH (IV), the 12-13 sequence, Z-Glu(OCMe3)-Leu-Gln-OH (V), the 9-11 sequence, H-Thr(CMe3)-Tyr(CMe3)-Gly-OH (VI), the 6-8 sequence, and BOC-Phe-Val-Pro-Ile-Pro-OH (VII), the 1-5 sequence, were also prepared II was coupled to III by DCC-HOSu to give the protected 14-22 sequence which was Z-deblocked and coupled to IV by DCC-HOSu to give the protected 12-22 sequence. The latter was Z-deblocked and coupled to V by DCC-HOSu to give the protected 9-11 sequence which was Z-deblocked and coupled to the protected 1-8 sequence to give the protected 1-22 sequence. The latter was deblocked with CF3CO2H to give I. The protected 1-8 sequence was prepared by coupling VI to VII by the HOSu active ester. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).COA of Formula: C10H19NO4

The Article related to leucine motiline, peptide motiline, Synthesis of Amino Acids, Peptides, and Proteins: Peptides and other aspects.COA of Formula: C10H19NO4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Wuensch, E.; Wendlberger, G.; Hallett, A.; Jaeger, E.; Knof, S.; Moroder, L.; Scharf, R.; Schmidt, I.; Thamm, P.; Wilschowitz, L. published an article in 1977, the title of the article was Total synthesis of human big gastrin I and the 32-leucine analog. (Preliminary communication).COA of Formula: C10H19NO4 And the article contains the following content:

Human big gastrin I (I) was prepared by coupling a protected 1-8 fragment to a protected 9-34 fragment (II) and deblocking the resulting protected 1-34 fragment. Protected peptide fragments related to sequences 9-14, 15-30, 21-22, 23-27, and 28-34 were prepared and used in the fragment peptide synthesis of II. The 32-leucine analog of I was also prepared The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).COA of Formula: C10H19NO4

The Article related to big gastrin i synthesis, Synthesis of Amino Acids, Peptides, and Proteins: Peptides and other aspects.COA of Formula: C10H19NO4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Cook, Ronald M.; Stevenson, David; Weinstein, Boris published an article in 1974, the title of the article was Amino acids and peptides. XXXVI. Synthesis of decapeptide sequence (A28-A37) of rubredoxin.Computed Properties of 53838-27-0 And the article contains the following content:

The protected rubredoxin A28-A37 fragment Bpoc-Ala-Phe-Glu(OCMe3)-Asp(OCMe3)-Val-Ser (OCMe3)-Glu-(OCMe3)-Asn-Trp-Val-OMe (I) (Bpoc = p-PhC6H4CMe2 O2C) was prepared by a 3 + 3 coupling sequence. Thus, PhCH2O2C-Val-Ser(OCMe3)-Glu(OCMe3)-OH, coupled with Asn-Trp-Val-OMe and removal of the PhCH2O2C group gave Val-Ser(OCMe2)-OMe and removal of the PhCH2O2C group gave Val-Ser(OCMe2)-Glu(OCMe3)-Asn-Trp-Val-OMe which was coupled with Ph-CH2O2C-Asp-(OCMe)3-OH and then with Bpoc-Ala-Phe-Glu-(OCMe3)-OH to give I. The fragment condensations occurred without racemization. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Computed Properties of 53838-27-0

The Article related to rubredoxin decapeptide, Synthesis of Amino Acids, Peptides, and Proteins: Peptides and other aspects.Computed Properties of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Widmer, Fred; Breddam, Klaus; Johansen, Jack T. published an article in 1980, the title of the article was Carboxypeptidase Y catalyzed peptide synthesis using amino acid alkyl esters as amine components.HPLC of Formula: 53838-27-0 And the article contains the following content:

Carboxypeptidase catalyzed peptide coupling reactions of Bz-Ala-OMe with amino acid alkyl esters and the peptide coupling of N-protected dipeptide Me esters with amino acid alkyl esters. The yield of peptide and the extent of oligomerization of the amine components depended on the nature of the amino acid side chains and the nature of the alkyl ester. The Me esters of hydrophobic amino acids oligomerized to various extents with total product yields of 60-90%, whereas the Me esters of hydrophilic amino acids did not oligomerize and gave peptides in 25-50% yields. As the size of the alkyl ester was increased, the degree of oligomerization was drastically decreased. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).HPLC of Formula: 53838-27-0

The Article related to carboxypeptidase catalyst peptide coupling, alkyl ester amino acid peptide carboxypeptidase, Synthesis of Amino Acids, Peptides, and Proteins: Peptides and other aspects.HPLC of Formula: 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 8, 1981, Meienhofer, Johannes Arnold published a patent.COA of Formula: C10H19NO4 The title of the patent was Peptides and their pharmaceutical preparations. And the patent contained the following:

Peptides H-X-Glu-Asn-OH (I; X = null, Ala, Glu-Ala, Glu-Glu-Ala, Val-Glu-Glu-Ala, Val-Val-Glu-Glu-Ala) were prepared as agents for influencing the regulation, differentiation, and function of thymus lymphocytes. Thus, Z-Ala-OH (Z = PhCH2O2C) was coupled to H-Glu(OCMe3)-Asn-OCMe3 by ClCO2CH2CHMe2 to give 81.7% Z-Ala-Glu(OCMe3)-Asn-OCMe3, which was Z-deblocked by hydrogenolysis over Pd/BaSO4 to give 96.8% H-Ala-Glu(OCMe3)-Asn-OCMe3, which was deblocked by CF3CO2H to give 60.4% H-Ala-Glu-Asn-OH. The effects of I on glucocorticoid resistance of mouse thymus cells were determined and these activities were compared to those of thymosin α1 and thymosin fraction 5. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).COA of Formula: C10H19NO4

The Article related to glutamylasparagine peptide preparation lymphocyte t differentiation, thymus cell glutamylasparagine peptide influence, Synthesis of Amino Acids, Peptides, and Proteins: Peptides and other aspects.COA of Formula: C10H19NO4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 28, 2006, Koppel, Gary A. published a patent.COA of Formula: C10H19NO4 The title of the patent was Preparation of β-lactams as vasopressin V1b antagonists.. And the patent contained the following:

Title compounds [I; A = carboxylic acid, ester, amide; B = A, alc, thiol, derivative thereof; R1 = H, alkyl; R2 = H, alkyl, alkoxy, alkylthio, cyano, CHO, alkylcarbonyl, etc.; R3 = (substituted) amino, amido, acylamido, ureido, N-containing heterocyclyl; R4 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkylcarbonyl, (substituted) aryl, aralkyl, arylhaloalkyl, aralkoxyalkyl, aralkenyl, aralkynyl, etc.], were prepared Thus, title compound [II; A = (R)-1,2,3,4-tetrahydronaphth-1-ylamino] [preparation using L-glutamic acid γ-tert-Bu ester-α-4-cyclohexylpiperazinylamide, cinnamaldehyde, and (S)-2-(4-phenyloxazolidin-2-on-3-yl)acetyl chloride outlined] showed rat V1b binding affinity with IC50 = 0.05 μM. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).COA of Formula: C10H19NO4

The Article related to beta lactam preparation vasopressin v1b antagonist, anxiety depression obsessive compulsive disorder impulsivity treatment azetidinone, Heterocyclic Compounds (One Hetero Atom): 4-Membered Rings and other aspects.COA of Formula: C10H19NO4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On July 2, 2009, Nazare, Marc; Zech, Gernot; Goerlitzer, Jochen; Just, Melitta; Weiss, Tilo; Hessler, Gerhard; Czechtizky, Werngard; Ruf, Sven published a patent.Synthetic Route of 53838-27-0 The title of the patent was Preparation of pyrazole-carboxamide derivatives as P2Y12 antagonists for treating cardiovascular disorders. And the patent contained the following:

The present invention relates to compounds of the formula I (wherein D is 3-15-membered heterocyclyl, (C6-C14)-aryl, etc.; Q and Z are -(C0-C4)-alkylene-O-(C0-C4)-alkylene-; -(C0-C4)-alkylene-SO2-(C0-C4)-alkylene-, etc.; J is H, (C1-C6)-alkyl, etc.; A is a covalent bond, (C1-C8)-alkylene, etc.; B is a covalent bond, (C2-C10)alkenyl, etc.; V is (un)substituted monocyclic or bicyclic 3-15-membered heterocyclyl; G is a covalent bond, (C2-C10)-alkenyl, etc.; M is H, (C1-C8)-alkyl, etc.; R1 is H or (C1-C4)alkyl; R2 is H, (C1-C6)alkyl, etc.). The compounds of the formula I are valuable pharmacol. active compounds They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them. Example compound II was prepared in a multistep synthesis that culminated in the conversion of the 5-(1-ethoxycarbonyl-cyclobutoxy) intermediate to II. In a human P2Y12 recombinant cell membrane binding assay, II had an IC50 of 0.601 μM. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Synthetic Route of 53838-27-0

The Article related to pyrazole carboxamide derivative preparation p2y12 antagonist treatment cardiovascular disorder, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Synthetic Route of 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics